DOCSLIB.ORG

Transdermal Estradiol Device and Delivery Transdermale Östradiolvorrichtung Und Freisetzung Dispositif D’Administration Transdermique D’Estradiol

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Transdermal Estradiol Device and Delivery Transdermale Östradiolvorrichtung Und Freisetzung Dispositif D’Administration Transdermique D’Estradiol (19) TZZ ¥_ZZZ__T (11) EP 2 310 001 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 9/70 (2006.01) A61K 31/565 (2006.01) 01.07.2015 Bulletin 2015/27 (86) International application number: (21) Application number: 09790211.8 PCT/US2009/050069 (22) Date of filing: 09.07.2009 (87) International publication number: WO 2010/006143 (14.01.2010 Gazette 2010/02) (54) TRANSDERMAL ESTRADIOL DEVICE AND DELIVERY TRANSDERMALE ÖSTRADIOLVORRICHTUNG UND FREISETZUNG DISPOSITIF D’ADMINISTRATION TRANSDERMIQUE D’ESTRADIOL (84) Designated Contracting States: (74) Representative: Zacco Denmark A/S AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Arne Jacobsens Allé 15 HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL 2300 Copenhagen S (DK) PT RO SE SI SK SM TR Designated Extension States: (56) References cited: AL BA RS US-A1- 2003 099 695 US-A1- 2005 202 073 US-A1- 2006 078 602 (30) Priority: 10.07.2008 US 216811 • Vivelle-Dot (estradiol transdermal system). (43) Date of publication of application: Continuousdelivery for twice weekly application. 20.04.2011 Bulletin 2011/16 Anonymous. Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936. Printed in (73) Proprietor: Noven Pharmaceuticals, INC. the USA. Pages 1-4. Miami, FL 33186 (US) Remarks: (72) Inventor: MANTELLE, Juan Thefile contains technical information submitted after Miami the application was filed and not included in this FL 33176 (US) specification Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention). EP 2 310 001 B1 Printed by Jouve, 75001 PARIS (FR) EP 2 310 001 B1 Description FIELD OF THE INVENTION 5 [0001] Described herein are compositions and methods for the transdermal delivery of estrogen. BACKGROUND [0002] This invention relates generally to transdermal drug delivery systems, and more particularly, to transdermal 10 drug delivery systems for the delivery of estrogen. The use of a transdermal system, for example, a patch comprising a pressure-sensitive adhesive containing a drug, as a means of delivering drug through the skin is well known. However, there remains a need for transdermal drug delivery systems designed for the delivery of specific drugs, such as estrogen, and there remains a particular need for smaller transdermal drug delivery systems that exhibit desired pharmacokinetic properties. 15 [0003] Transdermal delivery systems (adhesive patches) as dosage forms have been the subject of a vast number of patent applications over the last 25 years, yielding many patents but few commercial products in comparison. To those working in the field, the relatively small number of commercial products is not surprising. Although regulatory, economic, and market hurdles play a role in limiting the number of products on the market, the task of developing a transdermal delivery system that achieves desired physical and pharmacokinetic parameters to satisfy physician and patient demand 20 is more daunting. Parameters to be considered during commercial product development may include drug solubility, drug stability (e.g., as may arise from interaction with other component materials and/or the environment), delivery of a therapeutic amount of drug at a desired delivery rate over the intended duration of use, adequate adhesion at the anatomical site of application, integrity (e.g., minimal curling, wrinkling, delaminating and slippage) with minimal discom- fort, irritation and sensitization both during use and during and after removal, and minimal residual adhesive (or other 25 components) after removal. Size also may be important from a manufacturing and patient viewpoint, and appearance may be important from a patient viewpoint. The physical manufacturing and production aspects of commercial product development (e.g., the identity and costs of materials, equipment, and labor) and supporting analytical methods required for regulatory compliance also can be significant. [0004] Of the physical parameters that are considered when developing a commercial transdermal drug delivery 30 system,size, e.g.,surface area atthe siteof application, is often dictated andlimited by other physicaland pharmacokineti c requirements, such as desired drug delivery rates and daily dosages. In general, it is easier to develop a relatively "large" transdermal drug delivery system that will achieve drug delivery at target therapeutic levels over an intended duration of therapy, than it is to develop a smaller transdermal drug delivery system that still exhibits acceptable pharmacokinetic properties. Still, because size directly impacts costs (e.g., costs of component materials, costs of packaging materials, 35 costs for production and manufacturing equipment, labor costs relative to product yield per run time, etc.) and patients generally prefer smaller systems to larger ones (both for aesthetic reasons and comfort, since a smaller surface may permit the use of less aggressive adhesives), there is a need for smaller transdermal drug delivery systems. [0005] US 2005/202073 A1 relates to a transdermal matrix patch comprising 0.175 mg/cm 2 estradiol. The patch is not monolithic and does not include a penetration enhancer. 40 [0006] US 2003/099695 A1 relates to a monolithic transdermal system comprising 0.175 mg/cm2 estradiol, silicone and polyacrylate adhesives and a penetration enhancer. [0007] US 2006/078602 A1 relates to a transdermal patch comprising 2 % estradiol. acrylic based and silicone based polymers and a penetration enhancer. [0008] Vivelle-Dot (estradiol transdermal system). Continuous delivery for twice weekly application. Novartis Pharma- 45 ceuticals Corporation, East Hanover, NJ 07936 relates to a monolithic transdermal patch comprising 0.156 mg/cm2 estradiol, acrylic and silicone adhesives and a penetration enhancer. SUMMARY 50 [0009] In accordance with one embodiment, there is provided a monolithic transdermal drug delivery system comprising a drug containing layer comprising a polymer matrix comprising estradiol as the only drug, wherein the monolithic system comprises a single polymer matrix layer comprising 2-25% by weight acrylic adhesive, 45-70% by weight silicone ad- hesive, 2-25% by weight soluble PVP, 5-15% penetration enhancer, and 0.1-10% by weight estradiol, all based on the total dry weight of the polymer matrix, and the system includes greater than 0.156 mg/cm2 estradiol and achieves an 55 estradiol flux that is greater than 0.01 mg/cm2/day, based on the active surface area of said drug containing layer, when measured using a skin permeation study using split thickness, cryo-preserved cadaver skin on modified Franz diffusion cells with the receptor filled with 7.5 mL of 0.9% NaCl and 0.01% NaN3 in deionized water maintained at a constant 32oC and magnetically stirred at approximately 300 rpm, with samples, at specified time points, or the receptor phase 2 EP 2 310 001 B1 (with complete replacement of the receptor phase) and quantified by high- performance liquid chromatography. In some embodiments, the polymer matrix comprises about 20% by weight acrylic adhesive, about 56.9% by weight silicone adhesive, about 7.5% by weight soluble PVP, about 6.0% by weight oleyl alcohol, about 8.0% by weight dipropylene glycol, and about 1.6 % by weight estradiol. In some embodiments, the acrylic adhesive and silicone adhesive are 5 present in a ratio of from about 1:2 to about 1:6, based on the total weight of the acrylic and s ilicone adhesives. [0010] In some embodiments, the penetration enhancer comprises oleyl alchol or dipropylene glycol, or both. [0011] In some embodiments, the polymer matrix comprises an amount of estradiol effective to deliver a therapeutically effective amount of estradiol over a period of time selected from the group consisting of at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days and at least 7 days. In some embodiments, the polymer 10 matrix comprises an amount of estradiol effective to deliver an amount of estradiol selected from the group consisting of about 0.025, 0.0375, 0.05, 0.075 and 0.1 mg/day. [0012] In some embodiments, the polymer matrix has a coat weight of greater than about 10 mg/cm2. In some em- bodiments, the polymer matrix has a coat weight selected from the group consisting of about 12.5 and about 15 mg/ cm 2. [0013] In some embodiments, the system has an active surface area that is about 60% of a size selected from the 15 group consisting of 2.5, 3.75, 5.0, 7.5 and 10.0 cm2 and is effective to deliver an amount of estradiol per day of about 0.025, 0.0375, 0.05, 0.075 and 0.1 mg/day, respectively. [0014] In accordance with some embodiments, there is provided a transdermal drug delivery system comprising a polymer matrix comprising estradiol, wherein the system has an active surface area that is about 60% of a size selected from the group consisting of 2.5, 3.75, 5.0, 7.5 and 10.0 cm2 and is effective to deliver an amount of estradiol per day 20 of about 0.025, 0.0375, 0.05, 0.075 and 0.1 mg/day, respectively. [0015] The delivery system of the invention may by used in a method for administering estradiol, comprising applying to the skin or mucosa of a subject in need thereof a transdermal drug delivery system as described herein, such as a transdermal drug delivery system comprising a drug-containing layer defining an active surface area and comprising a polymer matrix comprising estradiol, wherein the system includes greater than 0.156 mg/cm 2 estradiol and achieves an 25 estradiol flux that is greater than 0.01 mg/cm2/day, based on the active surface area.
Load more

Recommended publications
  • Estradiol-17Β Pharmacokinetics and Histological Assessment Of
    animals Article Estradiol-17β Pharmacokinetics and Histological Assessment of the Ovaries and Uterine Horns following Intramuscular Administration of Estradiol Cypionate in Feral Cats Timothy H. Hyndman 1,* , Kelly L. Algar 1, Andrew P. Woodward 2, Flaminia Coiacetto 1 , Jordan O. Hampton 1,2 , Donald Nickels 3, Neil Hamilton 4, Anne Barnes 1 and David Algar 4 1 School of Veterinary Medicine, Murdoch University, Murdoch 6150, Australia; [email protected] (K.L.A.); [email protected] (F.C.); [email protected] (J.O.H.); [email protected] (A.B.) 2 Faculty of Veterinary and Agricultural Sciences, University of Melbourne, Melbourne 3030, Australia; [email protected] 3 Lancelin Veterinary Hospital, Lancelin 6044, Australia; [email protected] 4 Department of Biodiversity, Conservation and Attractions, Locked Bag 104, Bentley Delivery Centre 6983, Australia; [email protected] (N.H.); [email protected] (D.A.) * Correspondence: [email protected] Received: 7 September 2020; Accepted: 17 September 2020; Published: 21 September 2020 Simple Summary: Feral cats (Felis catus) have a devastating impact on Australian native fauna. Several programs exist to control their numbers through lethal removal, using tools such as baiting with toxins. Adult male cats are especially difficult to control. We hypothesized that one way to capture these male cats is to lure them using female cats. As female cats are seasonal breeders, a method is needed to artificially induce reproductive (estrous) behavior so that they could be used for this purpose year-round (i.e., regardless of season).
    [Show full text]
  • Structure and Origin of Uterine and Extragenital L=Ibroids Induced
    Structure and Origin of Uterine and Extragenital l=ibroids Induced Experimentally in the Guinea Pig by Prolonged Administration of Estrogens* Alexander Lipschotz, M.D., and Louis Vargas, Jr., M.D. (From Department o/ Experimental Medicine, National Health Service o/the Republic o/Chile, Santiago, Chile) (Received for publication December 13, x94o) The purpose of this communication is to present the These experimentally induced abdominal tumors findings of a detailed microscopical study of the sites present a smooth surface formed of a capsule com- of origin and stages of development of the subserous posed of flattened superficial cells (Plate 2, Figs. 2-A fibroid tumors induced in guinea pigs by prolonged and 2-B). The cells beneath the capsule resemble administration of estrogens. Details of treatment of fibroblasts. These cells have definite boundaries or the animals are given in the explanations of Plates I- 5. they are separated from each other by collagenous Subserous uterine tumors which can be induced in fibers (Plate 4, Fig. ix-C). guinea pigs by prolonged administration of estrogens, The masses of fibroid tumors arising from the apex as described by Nelson (26, 27), were found to be of the uterine horn may enclose the tubes or large fibroids. Lipschiitz, Iglesias, and Vargas (i3, 18, 22) tubal cysts. The demarcation between the muscular have shown that extragenital tumors in the abdominal coat of the tube and the tumor is not always sharp. cavity, induced by estrogens, also were fibroids. The In some instances, especially when the apical fibroid localization of these tumo~:s at various sites on the is small, the tumor is in close contact with an abun- uterus, pancreas, kidney, spleen, etc., have been de- dance of smooth muscle and adipose tissue (Plate 2, scribed by Iglesias (5), Vargas and Lipschiitz (32), Fig.
    [Show full text]
  • New Pharmacological Treatments for Equine Reproductive Management
    New Pharmacological Treatments for Equine Reproductive Management P. J. Burns, Ph.D.11,2,3,4, D. L. Thompson, Jr, Ph.D.5, W. A. Storer Ph.D.5 R. Gilley B.S1,2,3., C. Morrow, D.V.M.3, J. Abraham, B. S. 7 & R. H. Douglas, Ph.D. 1,2,3 1BioRelease Technologies LLC, Birmingham, AL 2BET Pharm, Lexington, KY 3 Mt Laurel Veterinary Pharmacy, Birmingham, 4Burns BioSolutions INC, Lexington, KY 5Animal Sciences Department, Louisiana State University, Baton Rouge, LA 6 Mobile Veterinary Practice, Amarillo, Tx, 7 Abraham Equine, Mendota Ranch, Canadian,Tx Introduction Loy (1970) reported that only 55% of mares bred annually produce live foals. Recent data from The Jockey Club (2006) indicate that only 37,025 of 64,123 (57.7%) of thoroughbred mares bred during 2005 produced live foals. This is considerably lower than foaling rates of 71 to 85%, which are reported on farms where extensive reproductive management is used. Overall, reproductive management has not improved much in the last 30 years. The long estrus period, with ovulation at any time from 1 to 10 days after the beginning of estrus, has made reproductive management of cyclic mares time-consuming, expensive and most importantly, inefficient. Furthermore, the confusion associated with the long and variable transition from anestrous to cyclicity in mares greatly magnifies the complexity of efficient reproductive management for this category of mares. There is a need to develop and capitalize on controlled breeding programs for the horse industry based on new advances in the understanding of cost effective hormonal control of reproduction in mares and stallions.
    [Show full text]
  • Pp375-430-Annex 1.Qxd
    ANNEX 1 CHEMICAL AND PHYSICAL DATA ON COMPOUNDS USED IN COMBINED ESTROGEN–PROGESTOGEN CONTRACEPTIVES AND HORMONAL MENOPAUSAL THERAPY Annex 1 describes the chemical and physical data, technical products, trends in produc- tion by region and uses of estrogens and progestogens in combined estrogen–progestogen contraceptives and hormonal menopausal therapy. Estrogens and progestogens are listed separately in alphabetical order. Trade names for these compounds alone and in combination are given in Annexes 2–4. Sales are listed according to the regions designated by WHO. These are: Africa: Algeria, Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic, Chad, Comoros, Congo, Côte d'Ivoire, Democratic Republic of the Congo, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Madagascar, Malawi, Mali, Mauritania, Mauritius, Mozambique, Namibia, Niger, Nigeria, Rwanda, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, South Africa, Swaziland, Togo, Uganda, United Republic of Tanzania, Zambia and Zimbabwe America (North): Canada, Central America (Antigua and Barbuda, Bahamas, Barbados, Belize, Costa Rica, Cuba, Dominica, El Salvador, Grenada, Guatemala, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Puerto Rico, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Trinidad and Tobago), United States of America America (South): Argentina, Bolivia, Brazil, Chile, Colombia, Dominican Republic, Ecuador, Guyana, Paraguay,
    [Show full text]
  • Progesterone and Estradiol Benzoate. (Iii) Limitations
    Food and Drug Administration, HHS § 522.1940 0.28 milligrams of isopropamide) in (ii) Indications for use. For increased buffered aqueous solution. rate of weight gain. (b) Sponsor. See No. 000069 in (iii) Limitations. For use in suckling § 510.600(c) of this chapter. beef calves (at least 45 days of age) up (c) Conditions of use. (1) The drug is to 400 pounds (lb) of body weight. For used in dogs and cats in which gastro- subcutaneous ear implantation, one intestinal disturbances are associated dose per animal. Do not use in bull with emotional stress. calves intended for reproduction. Safe- (2) Dosage is administered by sub- ty and effectiveness have not been es- cutaneous injection twice daily as fol- tablished in veal calves. A withdrawal lows: period has not been established for this product in preruminating calves. Do Dosage in Weight of animal in pounds Milliliters not use in calves to be processed for veal. Up to 4 ................................................................. 0.25 (2) Steers—(i) Amount—(A) 200 mg pro- 5 to 14 ................................................................. 0.5–1 15 to 30 ............................................................... 2–3 gesterone and 20 mg estradiol benzoate 30 to 45 ............................................................... 3–4 (one implant consisting of 8 pellets, 45 to 60 ............................................................... 4–5 each pellet containing 25 mg progester- Over 60 ................................................................ 6 one and 2.5 mg estradiol benzoate) per implant dose. Following the last injection, admin- (B) 200 mg progesterone and 20 mg es- ister prochlorperazine and tradiol benzoate (one implant con- isopropamide sustained release cap- sisting of 9 pellets, each of 8 pellets sules as indicated. containing 25 mg progesterone and 2.5 (3) For use only by or on the order of mg estradiol benzoate, and 1 pellet con- a licensed veterinarian.
    [Show full text]
  • Profiles of Circulating Estradiol-17Β After Different Estrogen Treatments in Lactating Dairy Cows
    Anim. Reprod., v.2, n.4, p.224-232, Oct./Dec. 2005 Profiles of circulating estradiol-17β after different estrogen treatments in lactating dairy cows A.H. Souza1, A.P. Cunha1, D.Z. Caraviello1, M.C. Wiltbank1,2 1Department of Dairy Science, 1675 Observatory Drive, University of Wisconsin, Madison, WI, USA 53706 Abstract Washburn et al., 2002). One of the physiological aspects that may affect reproductive efficiency in The objective of this study was to characterize lactating dairy cows is the elevated metabolism of the circulating concentrations of estradiol-17β (E-17β) estradiol-17β (E-17β; Sangsritavong et al., 2002). This after treatment with different types or doses of estrogens high E-17β metabolism appears to be due to the in the absence (Experiment 1) or presence (Experiment 2) elevated liver blood flow that is coincident with of a dominant follicle in lactating cows. In Experiment 1, elevated dry matter intake in lactating dairy cows cows (n = 12) had all follicles > 5 mm removed by (Sangsritavong et al., 2002). High rates of E-17β ultrasound-guided follicular aspiration every 12 h metabolism result in reduced circulating E-17β throughout the blood sampling period. Estrogen concentrations in lactating cows compared to non- treatments started 48 h after the first follicular aspiration. lactating cows (Sartori et al., 2002a; 2004) and in Treatments were: no treatment, E-17β (0.5 mg), or lactating cows with high milk production compared to estradiol benzoate (EB, 0.5 mg). Seven days after the cows with low production (Lopez et al., 2004; 2005). end of the first trial, cows were then re-randomized to Since E-17β is involved in many aspects of reproductive receive: no treatment, E-17β (1.0 mg), EB (1.0 mg), or physiology, this reduction in circulating E-17β could estradiol cypionate (ECP, 1.0 mg).
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,022,053 B2 Mueller Et Al
    US008022053B2 (12) United States Patent (10) Patent No.: US 8,022,053 B2 Mueller et al. (45) Date of Patent: Sep. 20, 2011 (54) ORAL SOLID DOSAGE FORMS CONTAINING 4,755,386 A 7, 1988 Hsiao et al. A LOW DOSE OF ESTRADIOL 5,073,374. A 12/1991 McCarty 5,776.492. A 7/1998 Betzing et al. 5,891,867 A * 4/1999 Lanquetin et al. ............ 514,170 (75) Inventors: Kristina Mueller, Berlin (DE); Torsten 5,891,868 A 4/1999 Cummings et al. Wagner, Berlin (DE); Adrian Funke, 6,030,988 A 2/2000 Gilis et al. Berlin (DE); Christian Zurth, Berlin 6,060,077 A * 5/2000 Meignant ...................... 424/434 (DE) 6,323,366 B1 1 1/2001 Wolfe et al. 6,326,366 B1* 12/2001 Potter et al. ................... 514, 182 6,455,069 B1 9, 2002 Michaud et al. (73) Assignee: Bayer Schering Pharma 6,521,253 B1 2/2003 Forsman et al. Aktiengesellschaft, Berlin (DE) 6,558,707 B1 5/2003 Thosar et al. 6,653,298 B2 * 1 1/2003 Potter et al. ................... 514, 182 (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 (Continued) U.S.C. 154(b) by 1017 days. FOREIGN PATENT DOCUMENTS (21) Appl. No.: 11/262,952 EP 04.078O140 11, 2004 (Continued) (22) Filed: Nov. 1, 2005 OTHER PUBLICATIONS (65) Prior Publication Data The Contraception Report, “Bioecuivalence between Brand-Name US 2006/O 111334 A1 May 25, 2006 and Generic OCs.” Jun. 2002, 13(2), 6-8.* Related U.S.
    [Show full text]
  • 21 CFR Ch. I (4–1–11 Edition) § 522.842
    § 522.842 21 CFR Ch. I (4–1–11 Edition) established in veal calves. A with- norgestomet and 5.0 milligrams of es- drawal period has not been established tradiol valerate per 2 milliliters. for this product in preruminating (b) Sponsor. See 050604 in § 510.600(c) of calves. Do not use in calves to be proc- this chapter. essed for veal. (c) Conditions of use—(1) Amount. One [69 FR 67818, Nov. 22, 2004] implant and 2 milliliters of injection at time of implantation. § 522.842 Estradiol benzoate and tes- (2) Indications for use. For synchroni- tosterone propionate. zation of estrus/ovulation in cycling (a) Sponsors. See sponsors in beef cattle and non-lactating dairy § 510.600(c) of this chapter for use as in heifers. paragraph (c) of this section. (3) Limitations. Insert implant (1) No. 000856 for use as in paragraph subcutaneously in the ear only; then (c)(1)(i), (c)(2), and (c)(3) of this section. immediately inject solution (2) No. 021641 for use as in paragraph intramuscularly only. Counting the (c) of this section. day of implantation as day 1, remove (b) Related tolerances. See §§ 556.240 the implant on day 10. Collect all im- and 556.710 of this chapter. plants as they are removed and burn (c) Conditions of use. For implanta- them. While animals are restrained for tion in heifers as follows: artificial insemination, avoid other (1) Amount. (i) 20 milligrams (mg) es- treatments such as vaccinations, dip- tradiol benzoate and 200 mg testos- ping, pour-on grub and louse preven- terone propionate (one implant con- tion, spraying, etc.
    [Show full text]
  • Other Data Relevant to an Evaluation of Carcinogenicity and Its Mechanisms
    COMBINED ESTROGEN−PROGESTOGEN CONTRACEPTIVES 143 4. Other Data Relevant to an Evaluation of Carcinogenicity and its Mechanisms 4.1 Absorption, distribution, metabolism and excretion in humans The metabolism and disposition of various formulations of oral contraceptives used in humans differ. After entering the small intestine, estrogenic and progestogenic compounds in combined oral contraceptives undergo metabolism by bacterial enzymes and enzymes in the intestinal mucosa to varying extents. The mixture of metabolized and unmetabolized compounds then undergoes intestinal absorption, and thus enters the portal vein blood, which perfuses the liver. In the liver, the compounds can be metabolized extensively, which leads to variations in the amount of active drug. A fraction of the absorbed dose of ethinyl- estradiol and some progestogens is also excreted in the bile during its first transit through the liver. Although some of these compounds are partially reabsorbed via the enterohepatic circulation, a fraction may also be excreted in this ‘first pass’, which reduces overall bio- availability. Since steroids penetrate normal skin easily, various systems have also been developed that deliver estrogens and progestogens parenterally, e.g. transdermal patches, nasal sprays, subcutaneous implants, vaginal rings and intrauterine devices (Fanchin et al., 1997; Dezarnaulds & Fraser, 2002; Meirik et al., 2003; Sarkar, 2003; Wildemeersch et al., 2003; Sturdee et al., 2004). These different modes of administration have been described previously (IARC, 1999). In general, all parenteral routes avoid loss of the drug by hepatic first-pass metabolism and minimally affect hepatic protein metabolism. The absorption rates of orally administered estrogens and progestogens are usually rapid; peak serum values are observed between 0.5 and 4 h after intake.
    [Show full text]
  • Federal Register/Vol. 65, No. 149/Wednesday, August
    47306 Federal Register / Vol. 65, No. 149 / Wednesday, August 2, 2000 / Rules and Regulations bench studies and clinical trials, other The Regulatory Flexibility Act PART 884ÐOBSTETRICAL AND relevant performance data, and labeling requires agencies to analyze regulatory GYNECOLOGICAL DEVICES will ensure that minimum levels of options that would minimize any performance, for both safety and significant impact of a rule on small 1. The authority citation for 21 CFR effectiveness, are addressed before entities. FDA knows of only one part 884 continues to read as follows: marketing clearance. Thus, persons who manufacturer of this type of device. Authority: 21 U.S.C. 351, 360, 360c, 360e, intend to market this device must Classification of these devices from 360j, 371. submit to FDA a premarket notification class III to class II will relieve this 2. Section 884.5970 is added to submission containing information on manufacturer of the device of the cost of subpart F to read as follows: the clitoral engorgement device before complying with the premarket approval marketing the device. requirements of section 515 of the act § 884.5970 Clitoral engorgement device. On April 28, 2000, FDA issued an (21 U.S.C. 360e) and may permit small (a) Identification. A clitoral order to the petitioner classifying potential competitors to enter the engorgement device is designed to apply Urometrics EROS±Clitoral Therapy marketplace by lowering their costs. The a vacuum to the clitoris. It is intended Device and substantially equivalent agency, therefore, certifies that the final for use in the treatment of female sexual devices of this generic type into class II rule will not have a significant impact arousal disorder.
    [Show full text]
  • Steroidal Estrogens
    FINAL Report on Carcinogens Background Document for Steroidal Estrogens December 13 - 14, 2000 Meeting of the NTP Board of Scientific Counselors Report on Carcinogens Subcommittee Prepared for the: U.S. Department of Health and Human Services Public Health Service National Toxicology Program Research Triangle Park, NC 27709 Prepared by: Technology Planning and Management Corporation Canterbury Hall, Suite 310 4815 Emperor Blvd Durham, NC 27703 Contract Number N01-ES-85421 Dec. 2000 RoC Background Document for Steroidal Estrogens Do not quote or cite Criteria for Listing Agents, Substances or Mixtures in the Report on Carcinogens U.S. Department of Health and Human Services National Toxicology Program Known to be Human Carcinogens: There is sufficient evidence of carcinogenicity from studies in humans, which indicates a causal relationship between exposure to the agent, substance or mixture and human cancer. Reasonably Anticipated to be Human Carcinogens: There is limited evidence of carcinogenicity from studies in humans which indicates that causal interpretation is credible but that alternative explanations such as chance, bias or confounding factors could not adequately be excluded; or There is sufficient evidence of carcinogenicity from studies in experimental animals which indicates there is an increased incidence of malignant and/or a combination of malignant and benign tumors: (1) in multiple species, or at multiple tissue sites, or (2) by multiple routes of exposure, or (3) to an unusual degree with regard to incidence, site or type of tumor or age at onset; or There is less than sufficient evidence of carcinogenicity in humans or laboratory animals, however; the agent, substance or mixture belongs to a well defined, structurally-related class of substances whose members are listed in a previous Report on Carcinogens as either a known to be human carcinogen, or reasonably anticipated to be human carcinogen or there is convincing relevant information that the agent acts through mechanisms indicating it would likely cause cancer in humans.
    [Show full text]
  • Early Refill Drug Utilization Review Drugs
    Early Refill Drug Utilization Review Drugs Published: 05/01/2012 Point-of-Sale Drug Authorization and Policy Drug Name Effective Date Override Override Center Override Acarbose X 11/8/2008 Acebutolol hydrochloride X 11/8/2008 acetaminophen X 11/8/2008 acetazolamide X 11/8/2008 acetazolamide sodium X 11/8/2008 acetylcholine X 11/8/2008 acetylcysteine X 11/8/2008 Acitretin X 11/8/2008 Acrivastine X 11/8/2008 activated charcoal X 11/8/2008 adalimumab X 11/8/2008 Adapalene X 11/8/2008 Adenosine X 11/8/2008 albumin human X 11/8/2008 Albuterol X 11/8/2008 albuterol sulfate X 11/8/2008 alclometasone dipropionate X 11/8/2008 aldesleukin X 11/8/2008 alendronate sodium X 11/8/2008 alfentanil hydrochloride X 11/8/2008 aliskiren hemifumarate X 11/8/2008 Alitretinoin X 11/8/2008 almotriptan malate X 11/8/2008 alosetron hydrochloride X 11/8/2008 Alprazolam X 1/6/2010 Aluminum X 11/8/2008 aluminum sulfate X 11/8/2008 amantadine hydrochloride X 11/8/2008 amcinonide X 11/8/2008 amino acids X 11/8/2008 aminophylline X 11/8/2008 amiodarone hydrochloride X 11/8/2008 amitriptyline hydrochloride X 11/8/2008 amlodipine besylate X 11/8/2008 Ammonium X 11/8/2008 Ammonium chloride X 11/8/2008 amobarbital X 1/6/2010 Point-of-Sale Drug Authorization and Policy Drug Name Effective Date Override Override Center Override Amoxicillin trihydrate X 11/8/2008 amphetamine X 1/6/2010 amyl nitrite X 11/8/2008 Amylase X 11/8/2008 apraclonidine hydrochloride X 11/8/2008 arformoterol tartrate X 11/8/2008 Arginine X 11/8/2008 arginine hydrochloride X 11/8/2008 aripiprazole X
    [Show full text]